checkAd

     153  0 Kommentare Tandem Mobi Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific Sessions

    Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today presented new real-world insights from a survey on Tandem Mobi user satisfaction and wearability during the 84th Scientific Sessions of the American Diabetes Association (ADA) taking place in Orlando, Florida. The survey found that 86 percent of participants were satisfied or very satisfied with Tandem Mobi regardless of prior therapy and agreed that Tandem Mobi helps improve their quality of life.1 Tandem Mobi, the world’s smallest, durable automated insulin delivery (AID) system, became commercially available in the United States in February of 2024.

    “These real-world user insights provide evidence that we are furthering our mission to improve the lives of people with diabetes by demonstrating that Tandem Mobi not only meets, but exceeds user expectations,” said Jordan Pinsker, MD, chief medical officer at Tandem Diabetes Care. “We are proud to share these results at ADA and will continue to innovate to provide the diabetes community with choice and improved quality of life.”

    In the six-week limited launch survey, early users who were previously using multiple daily injections (MDI), other insulin pumps (tubed and tubeless), or were previous Tandem pump users, also exhibited high satisfaction with the unique wearability features of Tandem Mobi combined with the Control-IQ algorithm. Tandem Mobi is so small that it can be worn almost anywhere2, giving users greater discretion, comfort, and flexibility. Meanwhile, Control-IQ technology predicts and helps prevent highs and lows.3

    Of prior MDI users:

    • 84 percent say Tandem Mobi reduces the burden of managing their diabetes
    • 82 percent say Tandem Mobi is easy to use
    • 77 percent say Tandem Mobi helps them feel they have more freedom in their lives

    Of prior pump users:

    • 78 percent say Tandem Mobi reduces the burden of managing their diabetes
    • 88 percent say Tandem Mobi is easy to use
    • 80 percent say Tandem Mobi helps them feel they have more freedom in their lives

    Barbara Davis Center Study of Early Users

    Also shared at ADA were insights from an independent study involving Tandem Mobi users. The results showed that time in range improved with no increase in time spent below range. For younger participants, form factor, portability, discreteness, and wearability are paramount to satisfaction and ongoing use. Tandem Mobi offers many options that support the needs of youth with type 1 diabetes, including:

    Seite 1 von 3



    Business Wire (engl.)
    0 Follower
    Autor folgen

    Weitere Artikel des Autors


    Tandem Mobi Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific Sessions Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today presented new real-world insights from a survey on Tandem Mobi user satisfaction and wearability during the 84th Scientific Sessions of the …